Clinical Study

CMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients

Table 2

Univariate analysis of risk factors for aGvHD and CMV reactivation/infection event(s) in patients post-alloHSCT.

VariableaGvHD value CMV absenceCMV presence value
≤grade I grade I Infection/reactivation until 1 year post-HSCT

Donor/recipient HLA match
 Matched11640P 11336P
Mismatched at the allele or  lowresolution levels up to two mismatches19252018

Source of HSCT
PBPC11161P 11248

Type of donor
 SIB6513P 6117P

Conditioning regimen
 RIC6728 6030

Donor CMV IgG
CMV IgG−3828P 3623P
 CMV IgG+96369631

Recipient CMV IgG
 CMV IgG−1913 244P
CMV IgG+1165210950

Donor-recipient IgG CMV serology
 R+/D−2820 2122P
 R−/D−, R+/D−, R−/D+, R+/D+10644 11132P

Donor/recipient gender
 Male to male, female to female, and male  to female10554 10544
 Female to male29112810

Donor gender
 Male7640 7532

Recipient gender
 Male7633 7127

Recipient age
 ≤16179 202P

CMV infection/reactivation event within 1 year post-HSCT
 CMV− 9736P

 aGvHD ≤ grade I9730P
aGvH rade I3624

EBV infection/reactivation event within 1 year post HSCT
 EBV−10042 10438

HHV6 infection/reactivation event within 1 year post HSCT
 HHV6−10350 11043 7

PBPC: peripheral blood progenitor cells; BM: bone marrow; R: recipient; D: donor; “−”: negative; “+”: positive; ATG: antithymocyte globulin; SIB: HLA-identical siblings; MUD: unrelated donors; RIC: reduced intensity conditioning.